Trastuzumab deruxtecan leads to longer overall survival than ramucirumab plus paclitaxel in HER2-positive gastric cancer

1. In this randomized controlled trial, among adults with HER2-positive unresectable or metastatic gastric cancer who had previously progressed on trastuzumab-based therapy, it was found that trastuzumab deruxtecan resulted in longer overall survival than ramucirumab plus paclitaxel. 2. The overall incidence of adverse events was similar between the two groups, although trastuzumab deruxtecan was associated […]